I trust that your readers can be reassured that the CEU is committed to providing objective summaries of available evidence as a service to Faculty members. Our documented code of practice precludes any relationships with pharmaceutical companies that might represent conflicting interests in our product reviews. In line with established principles of evidence-based medicine, we do not make clinical practice recommendations based on assumptions, personal beliefs or inappropriate extrapolations from research data. On this basis, we stand by our published conclusions and recommendations regarding the desogestrel pill.

Gillian Pennick, FRCP, MFFP
Honorary Director, Clinical Effectiveness Unit, Faculty of Family Planning and Reproductive Care, Aberdeen Maternity Hospital, Cornhill Road, Aberdeen AB25 2ZD, UK

References

New GyneFix® introducer
Madam
We wish to share our experience with the new GyneFix® introducer.

The Abacus Centre in Liverpool was the first service to offer the frameless intrauterine device, GyneFix in the UK, when it was introduced in 1997. To date we have fitted 1750 of these devices. Our audit of the first 100 insertions showed we had 11 failed insertions (of the 1000). Since the introduction of the new GyneFix introducer in our service in early 2003 we have had no reported report of failed insertion by all doctors carrying out insertions in our service. Initially we considered this to be part of the learning curve with the introduction of a new device. However, when the failed insertions continued, we undertook an audit of failed GyneFix insertions from January 2003 to August 2003. During this period there were 50 attempted GyneFix insertions of which 38 were successful and 12 failed to anchor to the device. In 7/8 successful insertions, there was more than one attempt to implant the GyneFix. We wasted 18 devices during the 50 attempted insertions. There was no indication that doctors with prior experience in GyneFix fitting had fewer failed insertions compared to those who had fitted fewer devices. This has raised difficulties in our counselling of women for GyneFix insertions as well as in our ability to continue to offer it as part of our contraceptive menu. We have reported these failed insertions to the manufacturer. We have heard from them that they have decreased the thickness of the plastic to help reduce this problem. However, this modification is only in the GyneFix 200, which only has four beads and for which there are few published long-term data.

We will be very interested to hear from other services as to whether they are experiencing similar problems with the new GyneFix introducer.

Andrea Brockmeyer, MRCOG, DFFP
Subspecialty Trainee; State Exam Med Tubingen/Germany, Abacus Clinics for Contraception and Reproductive Health Care, Liverpool, UK

Changes to cervical cytology screening
Liquid-based cytology will now be the preferred method of examination. In this method of screening the sample is collected from the cervix in the same way, but using a special plastic boric-like device which is swept over the transitional zone five times to collect cellular material. The boric is rinsed or broken off in a vial of preservative. The vial is mixed in the laboratory and treated to remove unwanted material by an automated process. The remaining suspension of cells can be stained and the prepared slide looks much clearer for examination. The number of unsatisfactory (inadequate) slides is reduced and fewer women will be made anxious by being recalled.

The frequency of screening will also be changed to a more equitable system. All women, wherever they live, are to be screened every 3 years from the age of 25–49 years, and then every 5 years until the age of 64 years. Further information is available at www.nice.org.uk.

Meera Kishen, DGO, Dip Ven, MFFP
Consultant in Family Planning and Reproductive Health Care, Abacus Clinics for Contraception and Reproductive Health Care, Liverpool, UK

Dieting and breakthrough bleeding on COCs
Madam
When dealing with the Margaret Pyke postbag, I was interested to receive a couple of queries requesting advice on the development of breakthrough bleeding (BTB) on combined oral contraceptives (COCs) in women who had a regular bleeding pattern until they went on diets and lost a lot of weight quite quickly. In one case, the Atkins diet (high protein, low carbohydrate) had been followed; in another, the woman was using Lighter Life® meal replacements. All other causes of BTB had been excluded.

I would be interested to know if other readers have come across this phenomenon and if they should add a question about dieting and weight loss to my list for women who present with BTB.

Anne MacGregor, MFFP
Medical Adviser, Margaret Pyke Memorial Trust, 73 Charlotte Street, London W1T 4PL, UK

NEWS ROUNDUP

A new IT solution for sexual health?
Information technology (IT) has been promoted as a panacea for all ills and sexual health is no exception. The technological boom is here to lend a helping hand to deal with the current sexual health crisis facing the country! The IBM partner, Appareo, aims to provide an effective, national, specialist, sexual health performance management system based around a data warehousing approach. The two critical elements are personal client data and clinical data and application.

The director assures us that the system will cater to the requirements of the national IT strategy and health care clinicians. Other benefits proposed are reduction in waiting times, improved patient access and an annual savings of £9 million.

The infrastructure needs to be clarified, in terms of the staff, resources and training. Should the responsibility for its smooth functioning rest with the already burdened clinicians or with new staff (with an added cost implication)? These issues warrant exhaustive thought before the adoption of such a system. For more details contact beyondpr@blueskyner.co.uk.

New national standards for HIV and AIDS care
Funded by the Department of Health, these standards were drawn up in line with the National Strategy for Sexual Health and HIV! The Medical Foundation for AIDS and Sexual Health (MedFASH), a charity sponsored by the British Medical Association, is publishing the standards. They cover all aspects of HIV care from prevention and diagnosis to palliative care. Each section of the standards was drawn up in line with the National Standards for Sexual Health and HIV. The standards are downloadable from www.medfash.org.uk.

Changes to cervical cytology screening
Liquid-based cytology will now be the preferred method of examination. In this method of screening the sample is collected from the cervix in the same way, but using a special plastic boric-like device which is swept over the transitional zone five times to collect cellular material. The boric is rinsed or broken off in a vial of preservative. The vial is mixed in the laboratory and treated to remove unwanted material by an automated process. The remaining suspension of cells can be stained and the prepared slide looks much clearer for examination. The number of unsatisfactory (inadequate) slides is reduced and fewer women will be made anxious by being recalled.

The frequency of screening will also be changed to a more equitable system. All women, wherever they live, are to be screened every 3 years from the age of 25–49 years, and then every 5 years until the age of 64 years. Further information is available at www.nice.org.uk.

Male contraception
Health professionals may have been perplexed by reports in the media about ‘The risk-free pill for men’ (Daily Mail) or ‘Male birth control pill successfully tested’ (The Daily Telegraph). These newspapers had picked up on a report from Australia that showed no pregnancies in the partners by the end of 12 months. The men received an injection of 150 mg depot medroxyprogesterone acetate once a year, together with an implant of 800 mg testosterone every 4 months. No serious side effects such as weight gain or hypertension were recorded in the 55 men studied. All male methods requiring sperm suppression have a long lead-in period, of course. It will be interesting to see if larger studies are as free from problems, such as mood swings and loss of libido, as the limited previous studies of this combination of therapies.

Further information on male contraception is available from www.malecontraceptives.org.

Four periods a year
Seasonale® has been approved by the Food and Drug Administration in the USA. It contains levonorgestrel and ethinyl oestradiol and is taken consecutively for 84 days, followed by seven pill-free days to produce a withdrawal bleed. Trials showed a similar effectiveness to conventional combined oral contraceptives. Some of the comment surrounding this alternative has suggested that it is healthier to avoid menstrual loss, a statement that cannot be backed by evidence at present. Making Seasonale available will expand women’s contraceptive options and increase convenience for some. This advance should not be undermined, however, by over-promising and over-promotion of this new form of contraception. More information is available from www.womenshealthnetwork.org.

Reviewed by Gill Wakley, MD, MFFP
Visiting Professor in Primary Care Development, Staffordshire University and Faculty General Practitioner and Wylde Green, Walsall, West Midlands, UK and P S Arumakumari, MD, MRCOG
Specialist Registrar in Obstetrics and Gynaecology, Rosie Maternity Hospital, Cambridge, UK

Letters / News Roundup

Journal of Family Planning and Reproductive Health Care 2004; 30(1)